Roth MKM Initiates Coverage On Chemomab Therapeutics with Buy Rating, Announces Price Target of $7
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Dylan Dupuis has initiated coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Buy rating and a price target of $7.
October 06, 2023 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chemomab Therapeutics has been initiated with a Buy rating by Roth MKM, with a price target of $7.
The initiation of coverage by Roth MKM with a Buy rating and a price target of $7 indicates a positive outlook for Chemomab Therapeutics. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100